COMMUNIQUÉS West-GlobeNewswire

WW International, Inc. Announces Fourth Quarter and Full Year 2024 Results

27/02/2025 - 22:01

Fourth Quarter 2024 Financial Highlights Total End of Period Subscribers of 3.3 million, including 92 thousand End of Period Clinical Subscribers Revenues of $184.4 million; Subscription Revenues down 7.3% vs. prior [...]

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

27/02/2025 - 22:01

– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second [...]

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

27/02/2025 - 22:01

Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under development Phase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollment ongoing in [...]

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

27/02/2025 - 22:01

Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Total Product Revenue [...]

Standard BioTools to Participate in Upcoming Investor Conferences

27/02/2025 - 22:01

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences: TD Cowen’s 45th Annual [...]

Progyny, Inc. Announces Fourth Quarter 2024 Results

27/02/2025 - 22:01

Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% Growth Generated $52.2 Million of Quarterly Operating Cash Flow Issues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW [...]

NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award

27/02/2025 - 22:03

TORONTO and HAIFA, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has been selected to present at [...]

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024

27/02/2025 - 22:03

Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreach Preparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Borderline [...]

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

27/02/2025 - 22:05

Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)- [...]

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

27/02/2025 - 22:05

Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 [...]

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

27/02/2025 - 22:05

FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth [...]

Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook

27/02/2025 - 22:05

Validated technology with exceptional growth of customer publications and enhanced access to the Proteograph Product Suite with growing demand for Seer Technology Access Center (STAC) REDWOOD CITY, Calif., Feb. 27, 2025 [...]

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

27/02/2025 - 22:05

— Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.m. ET — PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- [...]

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

27/02/2025 - 22:05

Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder Engagement Efforts Expecting to Initiate Four Late-Stage Trials and [...]

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

27/02/2025 - 22:05

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a [...]

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

27/02/2025 - 22:05

– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline [...]

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

27/02/2025 - 22:05

DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]

Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results

27/02/2025 - 22:05

Total revenue of $59.3 million for the fiscal year ended December 31, 2024 Expect double digit growth for total revenue in 2025 2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase [...]

Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance

27/02/2025 - 22:05

Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well [...]